Center for Healthcare Delivery Sciences (C4HDS), Brigham and Women's Hospital, Boston MA; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Center for Healthcare Delivery Sciences (C4HDS), Brigham and Women's Hospital, Boston MA; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Am Heart J. 2023 Feb;256:51-59. doi: 10.1016/j.ahj.2022.10.083. Epub 2022 Oct 28.
Accurate methods of identifying patients with suboptimal adherence to cardiometabolic medications are needed, and each approach has benefits and tradeoffs.
We used data from a large trial of patients with poorly controlled cardiometabolic disease and evidence of medication non-adherence measured using pharmacy claims data whose adherence was subsequently assessed during a telephone consultation with a clinical pharmacist. We then evaluated if the pharmacist assessment agreed with the non-adherence measured using claims. When pharmacist and claims assessments disagreed, we identified reasons why claims were insufficient and used multivariable modified Poisson regression to identify patient characteristics associated with disagreement.
Of 1,069 patients identified as non-adherent using claims (proportion of days covered [PDC] <80%), 646 (60.4%) were confirmed as non-adherent on pharmacist interview. For the 423 patients (39.6%) where the interview disagreed with the claims, the most common reasons were paying cash or using an alternate insurance (36.6%), medication discontinuation or regimen change (32.8%), and recently becoming adherent (26.7%). Compared to patients whose claims and interview both showed non-adherence, patients whose interview disagreed with claims were less likely to miss outpatient office visits (RR:0.91, 95%CI:0.85-0.97) and more likely to have a baseline PDC above the median (RR:1.35, 95%CI:1.10-1.64).
Among patients identified as non-adherent by claims, 39.6% were observed to be adherent when assessed during pharmacist consultation. This discrepancy was largely driven by paying out-of-pocket, using alternative insurance, or medication discontinuation or change. These findings have important implications for using pharmacy claims to identify and intervene upon medication non-adherence.
需要准确的方法来识别心血管代谢药物治疗依从性差的患者,每种方法都有其优点和缺点。
我们使用了一项大型临床试验的数据,该试验纳入了心血管代谢疾病控制不佳且存在药物使用非依从性证据的患者,其药物使用非依从性是通过使用药房索赔数据进行衡量的,随后在与临床药剂师的电话咨询中评估了其药物使用依从性。然后,我们评估了药剂师评估与使用索赔数据衡量的药物使用非依从性是否一致。当药剂师和索赔评估结果不一致时,我们确定了索赔数据不足的原因,并使用多变量修正泊松回归确定了与不一致相关的患者特征。
在使用索赔数据(覆盖天数[PDC]<80%)识别出的 1069 名非依从性患者中,有 646 名(60.4%)在药剂师访谈中被确认为非依从性。在与索赔数据不一致的 423 名患者(39.6%)中,最常见的原因是现金支付或使用替代保险(36.6%)、药物停药或方案改变(32.8%)和最近变得依从(26.7%)。与索赔和访谈均显示非依从性的患者相比,访谈结果与索赔结果不一致的患者错过门诊就诊的可能性较低(RR:0.91,95%CI:0.85-0.97),而基线 PDC 高于中位数的可能性较高(RR:1.35,95%CI:1.10-1.64)。
在使用索赔数据识别为非依从性的患者中,有 39.6%在接受药剂师咨询时被评估为依从性。这种差异主要是由于自费支付、使用替代保险、药物停药或改变。这些发现对使用药房索赔数据识别和干预药物使用非依从性具有重要意义。